Comparing high altitude treatment with current best care in children with Atopic Dermatitis (AD) and asthma within the atopic syndrome by the Wilhelmina Children?s Hospital, Utrecht-Dutch Asthma Centre, DAVOS

A pragmatic randomized controlled trial comparing high altitude treatment with current best care in children with moderate to severe atopic dermatitis (and asthma) in the Netherlands: multidisciplinary treatment at the high altitude clinic Dutch Asthma Centre Davos, Switzerland versus the Wilhelmina Children?s Hospital Utrecht, the Netherlands

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN88136485

Enrollment

Registered

2013-05-22

Start date

2010-09-01

Completion date

Unknown

Last updated

2019-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis and asthma within the atopic syndrome Skin and Connective Tissue Diseases Atopic dermatitis

Interventions

Intervention: multidisciplinary treatment at the Dutch Asthma Centre in Davos, Switzerland for 6 weeks Active control: multidisciplinary treatment at the outpatient clinic of the pedia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Moderate to severe atopic dermatitis 2. 8-18 years 3. Be able to speak and write in Dutch 4. Internet access and be able to use the Digital Eczema Center Utrecht 5. Willing to stay for 6 weeks in the Dutch Asthma Centre Davos

Exclusion criteria

Exclusion criteria: Current participation in another study

Design outcomes

Primary

Measure	Time frame
Current primary outcome measures as of 03/12/2013: 1. Disease coping and acceptance, measured with the COPEKI/JUCCKI questionnaire 2. Disease-specific quality of life, measured with Children's Dermatology Life Quality Index (CDQLI) 3. Self Administered Eczema Area and Severity Index (SA-EASI) All measured before the intervention, directly after the intervention, 6 weeks after the intervention and 6 months after the intervention Previous primary outcome measures: 1. Disease coping and acceptance, measured with the COPEKI/JUCCKI questionnaire directly after the intervention and 6 months after the intervention 2. Disease-specific quality of life, measured with Children's Dermatology Life Quality Index (CDQLI) directly after the intervention, 6 weeks after the intervention and 6 months after the intervention	—

Measure

Time frame

Current primary outcome measures as of 03/12/2013: 1. Disease coping and acceptance, measured with the COPEKI/JUCCKI questionnaire 2. Disease-specific quality of life, measured with Children's Dermatology Life Quality Index (CDQLI) 3. Self Administered Eczema Area and Severity Index (SA-EASI) All measured before the intervention, directly after the intervention, 6 weeks after the intervention and 6 months after the intervention Previous primary outcome measures: 1. Disease coping and acceptance, measured with the COPEKI/JUCCKI questionnaire directly after the intervention and 6 months after the intervention 2. Disease-specific quality of life, measured with Children's Dermatology Life Quality Index (CDQLI) directly after the intervention, 6 weeks after the intervention and 6 months after the intervention

—

Secondary

Measure	Time frame
Current secondary outcome measures as of 03/12/2013: 1. Disease activity and disease control (for AD and asthma), measured with 1.1. Used (topical) corticosteroids 1.2. Paediatric Asthma Quality of Life Questionnaire (PAQLQ) 1.3. Asthma Control Questionnaire (ACQ) 1.4. Lung function test (spirometry) 1.5. Fractional exhaled Nitric Oxide (FeNO) 1.6. Used asthma medication All measured before, directly after the intervention, 6 weeks and 6 months after the intervention 1.7. Bronchial hyperresponsiveness (metacholine provocation test) Measured before intervention and 6 months after intervention 2. Inflammatory and immunological profile, measured with serum levels of Thymus and Activation and Regulated Chemokine (TARC), cytokine profile (Th1/Th2) and eosinophil levels. Measured before, directly after intervention, 6 weeks and 6 months after the intervention 3. Social and emotional wellbeing of the child and quality of life of the parents, including parental stress and fear. Measured before, directly after intervention, 6 weeks and 6 months after the intervention 4. Other: 4.1. Bacterial colonization of the skin and nose, protease activity in skin Measured before the intervention, directly after the intervention, 6 weeks and 6 months after the intervention 4.2. Physical condition (maximal cycle ergometer test) before intervention and 6 months after the intervention 4.3. Extra appointments with the dermatologist/e-consultations/visits to the hospital are recorded during the follow-up period Previous secondary outcome measures: 1. Disease activity and disease control (for AD and asthma), measured with 1.1. Self Administered Ec	—

Measure

Time frame

Current secondary outcome measures as of 03/12/2013: 1. Disease activity and disease control (for AD and asthma), measured with 1.1. Used (topical) corticosteroids 1.2. Paediatric Asthma Quality of Life Questionnaire (PAQLQ) 1.3. Asthma Control Questionnaire (ACQ) 1.4. Lung function test (spirometry) 1.5. Fractional exhaled Nitric Oxide (FeNO) 1.6. Used asthma medication All measured before, directly after the intervention, 6 weeks and 6 months after the intervention 1.7. Bronchial hyperresponsiveness (metacholine provocation test) Measured before intervention and 6 months after intervention 2. Inflammatory and immunological profile, measured with serum levels of Thymus and Activation and Regulated Chemokine (TARC), cytokine profile (Th1/Th2) and eosinophil levels. Measured before, directly after intervention, 6 weeks and 6 months after the intervention 3. Social and emotional wellbeing of the child and quality of life of the parents, including parental stress and fear. Measured before, directly after intervention, 6 weeks and 6 months after the intervention 4. Other: 4.1. Bacterial colonization of the skin and nose, protease activity in skin Measured before the intervention, directly after the intervention, 6 weeks and 6 months after the intervention 4.2. Physical condition (maximal cycle ergometer test) before intervention and 6 months after the intervention 4.3. Extra appointments with the dermatologist/e-consultations/visits to the hospital are recorded during the follow-up period Previous secondary outcome measures: 1. Disease activity and disease control (for AD and asthma), measured with 1.1. Self Administered Ec

—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 21, 2026